This is only a brief summary of general information about this medicine
In 2026, the pace of scientific discovery is relentless
Interestingly, 78c showed no activity against ADP-ribosyl cyclase at concentrations up to 50 nM, while it exhibited no modulatory effects on CD157, suggesting its specificity toward CD38 139
doi: 10.1101/cshperspect.a014415 6 Ruiz-PrezMVHenleyABArsenian-HenrikssonM
High Entrapment Efficiency : We utilize advanced loading techniques to maximize the amount of GHK-Cu inside the liposomes, reducing waste and ensuring a potent final product
Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy